| 2016-11-30 07:03:49|
MRK 07:03 11/30 11/30/16
Merck announces new KEYTRUDA data to be presented at 17th WCLC
Merck announced that new data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, December 4-7. The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including over 200 trials that combine KEYTRUDA with other cancer treatments. Merck has an extensive research program in NSCLC and is currently advancing multiple registration-enabling studies with KEYTRUDA as monotherapy and in combination, the company said.